Specialisation in gastroenterology and expansion into oncology
First written in FY2018. 8 of 14 entries say "Advanced", first in FY2021-Q3. Latest entry: 2026-05-29.
No other company in this theme has enough history to compare yet.
- 2026-05-29AdvancedGeneral Meetings of Shareholders
「「ディフィクリア」は、市場規模の大きなフランスやドイツなどを中心に引き続き増収となりました。」
ディフィクリアの欧州展開について、フランス・ドイツなどを中心とする増収が記載された。 - FY2025-H1AdvancedAnnual report
「Sales of Dificlir (domestic brand name: Dafclir) increased substantially in countries including France, Germany and the United Kingdom.」
Sales of Dificlir, a key gastroenterology product, increased substantially in countries including France, Germany and the United Kingdom. - FY2024-Q1AdvancedAnnual report
「As a result of continuing to actively deploy sales resources for Dificlir, a treatment for Clostridioides difficile infection, in overseas markets, sales increased substantially in countries including France, Spain and the United Kingdom. In Japan, the company also took over the marketing authorisation from Astellas Pharma Inc. in April 2023 and began sales under the domestic brand name Dafclir.」
Within the gastroenterology product portfolio, Dificlir's sales increased substantially in countries including France, Spain and the United Kingdom, while sales in Japan began following the transfer of the marketing authorisation in April 2023. - FY2023AdvancedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection, is recommended as a first-line treatment in European infectious disease treatment guidelines. As a result of actively deploying sales resources, sales increased substantially. In April 2023, the company took over the marketing authorisation for Dafclir and began sales.」
The gastroenterology product portfolio advanced through the expansion of Dificlir's sales in Europe and the transfer of Dafclir's marketing authorisation and launch of sales in Japan. - FY2023-Q2AdvancedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection, is recommended as a first-line treatment in European infectious disease treatment guidelines. As a result of actively deploying sales resources, sales increased substantially.」
Sales of Dificlir, which was added to the gastroenterology product portfolio, increased substantially as a result of the active deployment of sales resources. - FY2023-Q1AdvancedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection, is recommended as a first-line treatment in European infectious disease treatment guidelines. As a result of actively deploying sales resources, sales increased substantially.」
Sales of Dificlir, which was added to the gastroenterology product portfolio, increased substantially, supported by its recommendation in treatment guidelines and the deployment of sales resources. - FY2022-Q3RestatedAnnual report
「Dificlir, a treatment for Clostridioides difficile infection for which the marketing rights in Europe, the Middle East and other regions were transferred from Astellas Pharma Europe Ltd. in November 2020, has completed the transfer procedures for marketing rights in major European countries and is making a significant contribution to sales.」
The company continues to report the completion of the transfer of Dificlir rights in major European countries and the product's contribution to sales, giving concrete form to its focus on gastroenterology. - FY2022-Q1AdvancedAnnual report
「The Clostridioides difficile infection treatment DIFICLIR, for which we succeeded to the manufacturing and marketing rights in Europe, the Middle East and other regions from Astellas Pharma Europe Ltd. in November last year, has completed the succession procedures in major European countries and is already making a significant contribution to sales.」
Procedures for transferring the rights to Dificlir in major European countries were completed, and the product made a significant contribution to sales as a new gastroenterology product. - FY2021-Q3AdvancedAnnual report
「We will develop it into one of the company's new core products by leveraging synergies with existing products.」
The company indicated a policy of developing Dificlir tablets into a new core product by leveraging synergies with its existing gastroenterology products, giving concrete form to its strategy of specialising in gastroenterology. - FY2020RestatedAnnual report
「In the prescription pharmaceuticals business, the company specialises in gastroenterology from research and development through sales, offering products across the upper and lower gastrointestinal tract. In research and development, it has selected oncology as the next area following gastroenterology and aims to strengthen its international competitiveness through this specialisation.」
The company continues its policy of specialising in gastroenterology and selecting oncology as the next research and development area. - FY2019RestatedAnnual report
「In the prescription pharmaceuticals business, the company specialises in gastroenterology from research and development through sales, offering products across the upper and lower gastrointestinal tract. In research and development, it has selected oncology as the next area following gastroenterology and aims to strengthen its international competitiveness through this specialisation.」
The company continues its policy of specialising in gastroenterology and selecting oncology as the next research and development area. - FY2019-Q3RestatedAnnual report
「The Company also began joint promotion of Infliximab BS for intravenous infusion 100 mg “Nichi-Iko” in November 2017 and is working to enhance its product lineup in the gastrointestinal field.」
Under its policy of specialising in gastroenterology, the company continues to enhance its product lineup through co-promotion. - FY2019-Q2RestatedAnnual report
「The Company also began joint promotion of Infliximab BS for intravenous infusion 100 mg “Nichi-Iko” in November 2017 and is working to enhance its product lineup in the gastrointestinal field.」
Under its policy of specialising in gastroenterology, the company continues to enhance its product lineup through co-promotion. - FY2018First statedAnnual report
「In the prescription pharmaceuticals business, the company specialises in gastroenterology from research and development through sales, offering products across the upper and lower gastrointestinal tract. In research and development, it has selected oncology as the next area following gastroenterology and aims to strengthen its international competitiveness through this specialisation.」
The company has identified a business-area strategy focused consistently on gastroenterology from the upper to lower gastrointestinal tract, with oncology selected as the next research and development area.